Current Medical Research and Opinion最新文献

筛选
英文 中文
A systematic review of the humanistic, economic, sociodemographic, and environmental burden of severe/difficult-to-treat asthma. 对严重/难治性哮喘的人文、经济、社会人口和环境负担的系统回顾。
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-06-18 DOI: 10.1080/03007995.2025.2513963
Arnaud Bourdin, Ioanna Vlachaki, Alessandra Madoni, Simon Donhauser, Marielle van der Deijl, Mithun Chakrawarthy Manne, Bala Ganesh Geddamuri, Nicola A Hanania
{"title":"A systematic review of the humanistic, economic, sociodemographic, and environmental burden of severe/difficult-to-treat asthma.","authors":"Arnaud Bourdin, Ioanna Vlachaki, Alessandra Madoni, Simon Donhauser, Marielle van der Deijl, Mithun Chakrawarthy Manne, Bala Ganesh Geddamuri, Nicola A Hanania","doi":"10.1080/03007995.2025.2513963","DOIUrl":"10.1080/03007995.2025.2513963","url":null,"abstract":"<p><strong>Objective: </strong>We examined gaps in our understanding of the health-related, humanistic, socioeconomic, and environmental burden of patients with difficult-to-treat/severe asthma.</p><p><strong>Methods: </strong>A systematic literature review was performed using Embase and MEDLINE. The searchs were performed separately for studies investigating humanistic and economic burden and those investigating environmental and sociodemographic impact, using a predefined search strategy. Study selection was based on the population, interventions, comparisons, outcomes, and study design framework. Data extraction from full-text publications was conducted using a standardized Microsoft Excel© template.</p><p><strong>Results: </strong>Fifty-two studies reporting the humanistic and economic burden and 11 studies reporting the environmental and sociodemographic impact were identified. Patients with severe vs non-severe asthma had lower quality of life (QoL). As expected, the impact of asthma on healthcare resource utilization and costs increased with disease severity. More frequent hospitalizations, emergency department visits, longer hospital length of stay, and higher frequency of exacerbations were seen in severe vs non-severe asthma. Eleven studies reported on factors such as air pollution and their association with increased risk of asthma severity, and there is a lack of evidence specifically addressing its impact on severe asthma.</p><p><strong>Conclusion: </strong>Severe asthma imposes significant economic and humanistic burdens on patients and healthcare systems. Both environmental and sociodemographic factors exacerbate asthma severity and should be further investigated to ensure optimal asthma management. Gaps remain in our knowledge of the impact of climate change on the most vulnerable patients with severe disease and our review highlights aspects of this burden that are still to be fully understood.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-21"},"PeriodicalIF":2.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of insulin adherence among patients with type 2 diabetes: a cross-sectional study. 2型糖尿病患者胰岛素依从性的预测因素:一项横断面研究
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-06-18 DOI: 10.1080/03007995.2025.2517697
Huda Jassim Muhammad, Radhwan M Hussein, Muntadher Zmezim, Ali Fawzi Al-Hussainy, Haneen Hussein Farhood, Iman Hussein Naser, Hamid Alghurabi
{"title":"Predictors of insulin adherence among patients with type 2 diabetes: a cross-sectional study.","authors":"Huda Jassim Muhammad, Radhwan M Hussein, Muntadher Zmezim, Ali Fawzi Al-Hussainy, Haneen Hussein Farhood, Iman Hussein Naser, Hamid Alghurabi","doi":"10.1080/03007995.2025.2517697","DOIUrl":"10.1080/03007995.2025.2517697","url":null,"abstract":"<p><strong>Objective: </strong>Type 2 diabetes (T2D) is a chronic metabolic disorder requiring insulin therapy as β-cell function declines. Despite insulin's proven efficacy, adherence remains a significant challenge. This study aims to identify factors influencing insulin adherence among patients with T2D to inform targeted clinical interventions.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at a tertiary diabetes clinic, recruiting adult patients with T2D on insulin therapy for at least six months. A structured, validated questionnaire was administered in person to collect demographic, clinical, and treatment-related data, along with patient beliefs about insulin. Insulin adherence was defined as taking ≥80% of prescribed doses over the past month. Statistical analysis included univariate and multivariate logistic regression to identify independent predictors of adherence.</p><p><strong>Results: </strong>Among 111 patients, 49 (44.1%) were adherent, while 62 (55.9%) were non-adherent. Adherence was associated with male gender, higher education levels, smoking abstinence, and adherence to recommended diet and exercise regimens. Non-adherent patients had a higher prevalence of family history of diabetes, more diabetic complications, increased comorbidities, and more frequent hospitalizations. Self-injection of insulin and regular self-monitoring of blood glucose were linked to better adherence, whereas fear of injections and the use of herbal medicine were associated with lower adherence. Negative beliefs about insulin were not significantly different between groups.</p><p><strong>Conclusion: </strong>Insulin adherence in T2D is influenced by lifestyle, clinical, and practical treatment factors rather than negative beliefs alone. Addressing practical barriers, such as fear of injection and alternative treatment use, through patient education and supportive interventions may improve adherence rates.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-13"},"PeriodicalIF":2.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Tislelizumab加化疗与安慰剂加化疗作为晚期胃或胃食管交界处腺癌的一线治疗:RATIONALE-305研究中患者报告的结果
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-06-18 DOI: 10.1080/03007995.2025.2501588
Marcia Cruz-Correa, Rui-Hua Xu, Markus Moehler, Do-Youn Oh, Ken Kato, David Spigel, Hendrik-Tobias Arkenau, Josep Tabernero, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Hidekazu Hirano, Lucjan Wyrwicz, Roberto Pazo Cid, Hui Xu, Tao Sheng, Gisoo Barnes
{"title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.","authors":"Marcia Cruz-Correa, Rui-Hua Xu, Markus Moehler, Do-Youn Oh, Ken Kato, David Spigel, Hendrik-Tobias Arkenau, Josep Tabernero, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Hidekazu Hirano, Lucjan Wyrwicz, Roberto Pazo Cid, Hui Xu, Tao Sheng, Gisoo Barnes","doi":"10.1080/03007995.2025.2501588","DOIUrl":"10.1080/03007995.2025.2501588","url":null,"abstract":"<p><strong>Objective: </strong>RATIONALE-305 (NCT03777657) demonstrated that tislelizumab plus chemotherapy statistically improved overall survival versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC). This analysis examined patient-reported outcomes (PROs) at final analysis.</p><p><strong>Methods: </strong>Adults with previously untreated, unresectable, or metastatic GC/GEJC were randomized (1:1) to tislelizumab or placebo intravenously once every 3 weeks plus chemotherapy. PROs assessed health-related quality of life (HRQoL) using EORTC QLQ-C30 and EORTC QLQ-STO22. A mixed model for repeated measures was used for PRO endpoints at treatment cycles 4 and 6, and time to deterioration was analyzed.</p><p><strong>Results: </strong>Tislelizumab arm had improved outcomes over placebo arm in least-squares (LS) mean change from baseline to cycle 6 for QLQ-C30 global health status/quality of life (GHS/QoL) (LS mean difference, 2.52 [95% CI: 0.29-4.74]), physical functioning (2.46 [0.49-4.43]), fatigue (-3.01 [-5.78 to -0.24]), and STO22 index score (-1.62 [-3.12 to -0.12]) as well as maintenance of upper gastrointestinal symptoms (-1.74 [-3.55-0.06]) and pain/discomfort (-1.88 [-4.03-0.27]). Patients receiving tislelizumab plus chemotherapy had a lower risk for deterioration of GHS/QoL (hazard ratio 0.77 [95% CI: 0.60-0.98]), physical functioning (0.72 [0.57-0.92]), STO22 index score (0.64 [0.45-0.92]), pain/discomfort (0.74 [0.58-0.96]), and upper gastrointestinal symptoms (0.73 [0.56-0.95]).</p><p><strong>Conclusions: </strong>Advanced GC/GEJC patients treated with tislelizumab plus chemotherapy versus placebo plus chemotherapy in first-line had sustained and improved HRQoL. These results, along with previous efficacy and safety data, support tislelizumab plus chemotherapy as a first-line treatment option for GC/GEJC.</p><p><strong>Trial registration: </strong>The RATIONALE-305 trial is registered on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT03777657).ClinicalTrials.gov identifier: NCT03777657.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: Final analysis from a prospective observational cohort study (ENDEAVOUR). 英国开始使用upadacitinib的中重度类风湿性关节炎患者的实际临床结果:来自一项前瞻性观察队列研究(奋进)的最终分析。
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-06-18 DOI: 10.1080/03007995.2025.2515280
James Taylor, Srinivasan Srirangan, Marwan Bukhari, Syed Bilgrami, Muhammad K Nisar, Stephen McDonald, Nicola Goodson, Andrew Allard, Alison Kinder, Michael Green, Laura Hunt, Sabrina Raizada, Bruce Kirkham, Eleri Thomas, Rachel Horsfall, Terri-Leigh Niblock, Victoria Burton, James Galloway
{"title":"Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: Final analysis from a prospective observational cohort study (ENDEAVOUR).","authors":"James Taylor, Srinivasan Srirangan, Marwan Bukhari, Syed Bilgrami, Muhammad K Nisar, Stephen McDonald, Nicola Goodson, Andrew Allard, Alison Kinder, Michael Green, Laura Hunt, Sabrina Raizada, Bruce Kirkham, Eleri Thomas, Rachel Horsfall, Terri-Leigh Niblock, Victoria Burton, James Galloway","doi":"10.1080/03007995.2025.2515280","DOIUrl":"https://doi.org/10.1080/03007995.2025.2515280","url":null,"abstract":"<p><strong>Objective: </strong>Upadacitinib is recommended by National Institute for Health and Care Excellence in the UK in adults with moderate-to-severe rheumatoid arthritis (RA). This observational study assessed real-world clinical outcomes and patient-reported outcomes (PROs) in patients receiving upadacitinib for 6 months in the UK.</p><p><strong>Methods: </strong>Patients from 14 centres in whom the decision to initiate upadacitinib had already been made were enrolled. Baseline data were retrospectively collected from patient records. Clinician-reported data were collected at routine clinic visits 3 and 6 months after upadacitinib initiation. Patient-reported data were collected directly from patients using an app (electronic PROs, ePROs). The primary end-point was proportion of patients achieving clinical remission (DAS28 CRP <2.6) after 6 months of upadacitinib.</p><p><strong>Results: </strong>Data are available for 63 patients at all three datapoints and for 53 patients for the primary end-point. At 6 months, 40% (21/53) of patients achieved clinical remission and 21% (11/53) achieved low disease activity. Response was seen at 3 months for all efficacy end-points. ePROs allowed the capture of early patient-reported data which demonstrated clinically important improvements in pain and fatigue within 10 days and other PROs within 2 months. Improvements were also seen in metrics of activity, work and quality of life (QOL).</p><p><strong>Conclusion: </strong>Patients in ENDEAVOUR showed similar early effectiveness with upadacitinib to that observed in clinical trials. Use of ePROs demonstrated rapid onset of action and meaningful improvements in QOL providing a potential opportunity to reduce outpatient visits for early responders, thus reducing the burden on rheumatology services.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-17"},"PeriodicalIF":2.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022). 医疗保健提供者和患者报告的比替替韦/恩曲他滨/替诺福韦与其他抗逆转录病毒治疗方案的结果:美国的一项观察性调查(2021年7月- 2022年3月)。
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-06-17 DOI: 10.1080/03007995.2025.2517692
Amy Colson, Megan Chen, Fritha Hennessy, Joshua Gruber, Woodie Zachry, Seojin Park, Tim Holbrook
{"title":"Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022).","authors":"Amy Colson, Megan Chen, Fritha Hennessy, Joshua Gruber, Woodie Zachry, Seojin Park, Tim Holbrook","doi":"10.1080/03007995.2025.2517692","DOIUrl":"https://doi.org/10.1080/03007995.2025.2517692","url":null,"abstract":"<p><strong>Objective: </strong>Given the chronic nature of HIV infection and the evolving treatment landscape, it is important to reexamine the impact of HIV medication choice on adherence, treatment satisfaction, and quality of life (QoL) for people with HIV (PWH). While bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is commonly prescribed, there are few observational data comparing treatment outcomes with other regimens. This study aimed to compare health care provider (HCP)- and PWH-reported outcomes for individuals prescribed B/F/TAF versus other antiretroviral therapy (ART) regimens.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World HIV Disease Specific Programme, an observational, cross-sectional survey of HCPs and PWH conducted from July 2021-March 2022 in the United States. PWH were aged ≥18 years with confirmed HIV diagnosis and a current ART prescription. Outcomes included HCP- and PWH-reported adherence, treatment satisfaction, QoL, and health care resource utilization (HCRU). Subgroups were based on ART regimen and treatment experience. Comparisons between subgroups were performed using the <i>t</i> test, chi-square test, Fisher's exact test, and Mann-Whitney test, as appropriate.</p><p><strong>Results: </strong>Sixty HCPs provided data for 600 PWH, and 249 PWH reported their experiences. Overall, 264 PWH were prescribed B/F/TAF, 281 were prescribed other single-tablet regimens (STRs) or a long-acting injectable (LAI), and 55 were prescribed a multi-tablet regimen. The two most common HCP-reported reasons for choice of ART were viral potency and tolerability. High treatment satisfaction was reported for B/F/TAF by both HCPs (61% \"very satisfied\" with B/F/TAF vs 53% with other STRs or an LAI; <i>P</i> = 0.0223) and PWH (57% vs 52%, respectively; <i>P</i> = 0.3170). PWH receiving B/F/TAF reported significantly higher QoL scores (PozQoL and EQ-5D-5L) and lower activity impairment versus PWH receiving other STRs or an LAI. Adherence rates and HCRU were generally similar between groups. PWH receiving B/F/TAF as their first ART regimen were significantly more likely to be \"completely adherent\" according to HCPs (<i>P</i> = 0.0098) and had significantly less testing-related HCRU (<i>P</i> < 0.0001) than treatment-experienced PWH receiving B/F/TAF. PWH who switched to B/F/TAF had less HCP-reported weight gain (<i>P</i> = 0.0266) and had lower testing-related HCRU (<i>P</i> = 0.0498) compared with those who switched to other ART.</p><p><strong>Conclusion: </strong>Positive HCP- and PWH-reported outcomes were seen across ART regimens. However, differences observed, including HCP-reported treatment satisfaction and PWH-reported QoL, favored B/F/TAF compared with other STRs or an LAI. These findings support continued use of B/F/TAF for HIV treatment in the United States. More patient-focused research with disease-specific outcome measures should be performed to further optimize treatment outcomes for PWH.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-17"},"PeriodicalIF":2.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new strategy for the selection of patients with hip osteoarthritis to avoid inappropriate total hip replacement based on imaging and clinical characteristics. 基于影像学和临床特征选择髋关节骨关节炎患者以避免不适当的全髋关节置换术的新策略。
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-06-17 DOI: 10.1080/03007995.2025.2521097
Kazuo Hayashi, Yves Henrotin, Toshiharu Tsunoda, Shoji Tokunaga
{"title":"A new strategy for the selection of patients with hip osteoarthritis to avoid inappropriate total hip replacement based on imaging and clinical characteristics.","authors":"Kazuo Hayashi, Yves Henrotin, Toshiharu Tsunoda, Shoji Tokunaga","doi":"10.1080/03007995.2025.2521097","DOIUrl":"https://doi.org/10.1080/03007995.2025.2521097","url":null,"abstract":"<p><strong>Background: </strong>Total hip replacement (THR) is extremely common and generally results in excellent patient satisfaction. However, 36% of patients with hip osteoarthritis who undergo THR reportedly experience long-term postoperative pain. Furthermore, only 20% of patients attempt exercise before surgery, despite the recommendation for 3 to 6 months of conservative treatment before surgery. Despite these facts, the number of THRs performed annually is currently increasing.</p><p><strong>Objectives: </strong>To propose and discuss a new strategy based on clinical and radiological characteristics for selecting candidates for Pericapsular Soft Tissue and Pelvic Realignment (PSTP-R) therapies to avoid inappropriate THR.</p><p><strong>Methods: </strong>The PubMed electronic database was searched to identify publications reporting data from clinical studies on the diagnosis and treatment of osteoarthritis in humans published between 1995 and 2023. This narrative review summarizes the findings of these previous studies.</p><p><strong>Results: </strong>A previous study reported that PSTP-R therapy comprising pelvic realignment, muscle strengthening, and stretching was effective for patients with a Harris Hip Score (HHS) below 60 points, even those with complete loss of cartilage on radiography. A post hoc study showed that the risk of discontinuation of PSTP-R therapy increased with increasing frequency of pain in the buttock at baseline. Cartilage loss was not a risk factor for withdrawal from PSTP-R therapy.</p><p><strong>Conclusion: </strong>Patients should be better informed regarding the benefits of THR and the possibility of persistent postoperative pain. If the patient has complete loss of cartilage on radiography but no buttock pain, PSTP-R therapy might improve their pain and avoid THR.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-15"},"PeriodicalIF":2.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GPP 2022: perspectives, sentiments, and feedback from the publications community. GPP 2022:来自出版界的观点、观点和反馈。
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-05-01 Epub Date: 2025-05-14 DOI: 10.1080/03007995.2025.2503975
Raghuraj Puthige, Dikran Toroser, Anisha Mehra, Dhanya Mukundan, Anupama Kapadia
{"title":"GPP 2022: perspectives, sentiments, and feedback from the publications community.","authors":"Raghuraj Puthige, Dikran Toroser, Anisha Mehra, Dhanya Mukundan, Anupama Kapadia","doi":"10.1080/03007995.2025.2503975","DOIUrl":"10.1080/03007995.2025.2503975","url":null,"abstract":"<p><strong>Objective: </strong>To identify the impact and integration of GPP 2022 guidelines on the work processes of publications developed in pharmaceutical, publishing, agency, and academic circles.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted for 3 weeks from March 1-22, 2024 among medical publication professionals and healthcare researchers. The survey included questions that have been traditionally challenging in publication workstreams and were disseminated through major medical communications networking groups. The survey results were summarized as a percentage for each answer rounded to one decimal place.</p><p><strong>Results: </strong>A total of 100 participants responded to the survey among whom 67.0% were familiar with the GPP 2022 guidelines. To mitigate potential misinterpretation risks, we considered only respondents familiar with the guidelines. More than half of the respondents (55.7%) felt that GPP 2022 was effective in addressing ethical considerations; 34.4% respondents agreed that GPP 2022 provided useful guidance on best practices in transparency and data-sharing. Most survey respondents (54.5%) agreed that the authorship and contributorship criteria were clear in GPP 2022. 37.3% of the survey respondents were familiar with publication extenders and felt that extenders added value to the dissemination of research findings; 39.2% were aware of plain-language summaries and 82.4% viewed them as vital for widespread research accessibility.</p><p><strong>Conclusion: </strong>The survey suggests a need to improve awareness and support for implementing transparency initiatives that aid in the publication process. Furthermore, although most respondents were aware of publication extenders, there was a need for clarification and harmonization of guidelines on publication extenders.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"879-885"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tobacco smoking and sarcoidosis revisited-Evidence, mechanisms, and clinical implications: a narrative review. 吸烟和结节病重新审视-证据,机制和临床意义:叙述性回顾。
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-05-01 Epub Date: 2025-05-06 DOI: 10.1080/03007995.2025.2495852
Nadia Sweis, Arnaud Dominati, Supritha Prasad, Fatima Alnaimat, Mina Alawqati, Israel Rubinstein, Rachel Caskey
{"title":"Tobacco smoking and sarcoidosis revisited-Evidence, mechanisms, and clinical implications: a narrative review.","authors":"Nadia Sweis, Arnaud Dominati, Supritha Prasad, Fatima Alnaimat, Mina Alawqati, Israel Rubinstein, Rachel Caskey","doi":"10.1080/03007995.2025.2495852","DOIUrl":"10.1080/03007995.2025.2495852","url":null,"abstract":"<p><p>Sarcoidosis is a multisystem inflammatory disease with unclear etiology, influenced by genetic predisposition and environmental exposures. Smoking has been widely studied for its potential role in sarcoidosis, with conflicting evidence regarding its impact on disease risk, severity, and treatment response. While some epidemiologic studies suggest that smoking is associated with a lower risk of sarcoidosis, others highlight variations based on geography, ethnicity, and smoking history. Assessing the effects of smoking is particularly challenging because of the complex composition of tobacco smoke, which contains thousands of chemicals with diverse biologic effects. Nicotine, a major component of tobacco, has demonstrated both pro- and anti-inflammatory properties, further complicating its role in sarcoidosis. This narrative review explored the complex relationship between smoking and sarcoidosis by examining smoking's effects on immune modulation, disease presentation and prognosis, and response to immunosuppressive therapy. By summarizing current evidence, this paper aimed to clarify the impact of smoking and nicotine on sarcoidosis and identify key areas for future research, particularly in understanding the mechanisms underlying smoking-related immune modulation and treatment outcomes.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"901-916"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of appetite loss and related factors in older patients with cancer: validation of the cancer appetite and symptom questionnaire (CASQ) in Turkish patients. 老年癌症患者食欲减退及相关因素的评估:土耳其患者癌症食欲及症状问卷(CASQ)的验证
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-05-01 Epub Date: 2025-05-16 DOI: 10.1080/03007995.2025.2502669
Digdem Dogan Akagunduz, Hilal Şahin, Ferhan Elmalı, Baran Akagunduz
{"title":"Assessment of appetite loss and related factors in older patients with cancer: validation of the cancer appetite and symptom questionnaire (CASQ) in Turkish patients.","authors":"Digdem Dogan Akagunduz, Hilal Şahin, Ferhan Elmalı, Baran Akagunduz","doi":"10.1080/03007995.2025.2502669","DOIUrl":"10.1080/03007995.2025.2502669","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to validate the Cancer Appetite and Symptom Questionnaire (CASQ) for Turkish older cancer patients and identify factors influencing appetite loss and related symptoms. The research question focused on whether the CASQ is a reliable tool for assessing appetite-related symptoms and determining associated risk factors in this population.</p><p><strong>Methods: </strong>A total of 240 cancer patients aged ≥70 years were recruited from a Turkish oncology clinic. Demographic, cancer-related, nutritional, functional, and psychological data were collected. Appetite was assessed using the CASQ and Simplified Nutritional Appetite Questionnaire (SNAQ). Structural validity, reliability, and diagnostic performance were evaluated through exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). Logistic regression was performed to identify factors associated with appetite loss.</p><p><strong>Results: </strong>The CASQ demonstrated high reliability and validity, with a Cronbach's alpha of 0.971 and Kaiser-Meyer-Olkin (KMO) of 0.907. EFA and CFA supported a single-factor structure. A CASQ cutoff score of 32 showed high diagnostic accuracy (AUC: 0.971) with 88.9% sensitivity. Appetite loss was reported in 53.7% of patients and was significantly associated with stage IV cancer (OR: 10.112, <i>p</i> < .001), chemotherapy (OR: 2.960, <i>p</i> = .016), severe pain (OR: 3.089, <i>p</i> = .003), malnutrition (OR: 4.459, <i>p</i> = .033), polypharmacy (OR: 2.213, <i>p</i> = .040), and poor performance status (OR: 5.245, <i>p</i> = .017).</p><p><strong>Conclusions: </strong>The CASQ is a validated, reliable tool for assessing appetite-related symptoms in Turkish older cancer patients. Findings underscore the need for integrated nutritional and psychological care. Future research should develop targeted interventions to mitigate appetite loss and its impact on quality of life in this population.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"789-797"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine. 功能改善作为重度抑郁障碍的治疗目标:沃替西汀证据的叙述性回顾。
IF 2.4 4区 医学
Current Medical Research and Opinion Pub Date : 2025-05-01 Epub Date: 2025-05-15 DOI: 10.1080/03007995.2025.2503976
Pratap Chokka, Lene Hammer-Helmich, Simon Nitschky Schmidt, Martine Hubert, Elin H Reines, Iria Grande
{"title":"Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine.","authors":"Pratap Chokka, Lene Hammer-Helmich, Simon Nitschky Schmidt, Martine Hubert, Elin H Reines, Iria Grande","doi":"10.1080/03007995.2025.2503976","DOIUrl":"10.1080/03007995.2025.2503976","url":null,"abstract":"<p><p>This narrative review used manufacturer-sponsored vortioxetine clinical trial database (doses of 5-20 mg) to evaluate the effect of vortioxetine treatment on short- and long- term functional outcomes in major depressive disorder (MDD), in both the clinical trial setting and in routine practice. The Sheehan Disability Scale (SDS) was the most used functional scale and, based on this measure, short-term, placebo-controlled studies demonstrated significant improvements with vortioxetine 10 mg (reductions ranged from -0.92 to -2.10 points vs placebo after 6-8 weeks treatment) and 20 mg (reductions ranged from -0.88 to -3.92 vs placebo). Of note, the acute beneficial effects of vortioxetine on functionality were seen in patients with severe baseline depressive symptoms as well as those with significant anxiety. Long-term open-label extension studies further showed that maintenance treatment was associated with continued functional improvements over one year (reaching an average reduction of -6.2 SDS points from baseline) that were correlated with continued improvements in residual symptoms. Evidence from real-world studies, using multiple functional outcomes, further demonstrated generalizability to routine practice where patients are living with multiple comorbidities previously excluded from the randomized controlled trials. Taken overall, the findings from several head-to-head studies indicated a functional advantage of vortioxetine compared with other classes of antidepressants and demonstrated the effectiveness of vortioxetine as first-line treatment while also confirming its effectiveness in improving functional outcomes when given later in the treatment journey. In summary, vortioxetine is an effective treatment option for improving functional outcomes in people living with MDD.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"855-866"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信